Neuroone Medical Technologies CORP Form 4 insider transactions

Mark Christianson, Market Development Director at NeuroOne Medical Technologies Corp., reported a transaction involving 10,000 shares of common stock.

NeuroOne Medical Technologies Corp reports director Jason Richard Mills acquired restricted stock units and stock options.

NeuroOne Medical Technologies Corp. reports a Form 4 filing detailing stock grants and options awarded to Director Jeffrey S. Mathiesen.

NeuroOne Medical Technologies Corp. reports a Form 4 filing detailing stock transactions by Director Paul Buckman, including the acquisition of restricted stock units and stock options.

NeuroOne Medical Technologies Corp. reports a Form 4 filing detailing stock transactions by Director Edward Andrle.

NEUROONE Medical Technologies' Business Development Director, Mark Christianson, reported the sale of common stock and shares withheld for tax purposes.

NeuroOne Medical Technologies Corp.'s Chief Technology Officer, Steve Mertens, disposed of 906 common shares to cover tax withholding obligations.

NeuroOne Medical Technologies CEO David A. Rosa disposed of 2,458 shares of common stock to cover tax liabilities.

NEUROONE MEDICAL TECHNOLOGIES Corp's Business Development Director, Mark Christianson, reported selling 917 shares of common stock.

NEUROONE Medical Technologies' Business Development Director, Mark Christianson, sold 13,720 shares of common stock in two transactions.

NeuroOne Medical Technologies' Chief Business Officer, David J. Wambeke, acquired 1,000,000 shares of common stock and 500,000 stock options, signaling increased confidence.

NEUROONE MEDICAL TECHNOLOGIES Corp's Chief Technology Officer, Steve Mertens, disposed of 906 common shares to cover tax liabilities.

NEUROONE MEDICAL TECHNOLOGIES Corp CEO David A. Rosa reported a disposition of 2,458 common shares for tax liability.

NeuroOne Medical Technologies' Business Development Director, Mark Christianson, disposed of 253 common shares to cover tax withholding obligations.

Jason Richard Mills, a Director at NeuroOne Medical Technologies Corp., was granted 7,758 shares of common stock and options to purchase 4,806 shares, vesting over one year.

NeuroOne Medical Technologies Corp. Chief Technology Officer Steve Mertens disposed of 906 common shares to cover tax withholding obligations.

NeuroOne Medical Technologies' Business Development Director, Mark Christianson, disposed of 253 common shares to cover tax liabilities at a price of $0.8886 per share.

NeuroOne Medical Technologies Corp. CEO David A. Rosa reported a disposal of 2,458 common shares on September 30, 2025, to satisfy tax liabilities.

NeuroOne Medical Technologies' Business Development Director, Mark Christianson, sold 30,000 shares of common stock at an average price of $0.7401.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies Corp, disposed of 253 shares of common stock to satisfy tax withholding obligations.

NeuroOne Medical Technologies Corp.'s Chief Technology Officer, Steve Mertens, reported the disposal of 906 common shares at $0.678 per share on June 30, 2025, for tax liability purposes.

NeuroOne Medical Technologies Corp's CEO and President, David A. Rosa, reported a disposition of 2,458 shares of common stock at $0.678 per share, primarily for tax liability, maintaining a beneficial ownership of 1,158,831 shares.

NeuroOne Medical Technologies Corp. Director Jeffrey S. Mathiesen was granted 50,000 stock options with an exercise price of $0.662, vesting over one year, as disclosed in a recent SEC Form 4 filing.

NeuroOne Medical Technologies Corp. Director Paul Buckman was granted 50,000 options to purchase common stock at an exercise price of $0.662, vesting over one year.

Edward Andrle, a Director at NeuroOne Medical Technologies Corp., was granted 50,000 options to purchase common stock with a vesting schedule over one year.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies Corp, has sold 10,000 shares of common stock for approximately $5,804, as disclosed in a recent SEC Form 4 filing.

Emily J. Johns, General Counsel of NeuroOne Medical Technologies Corp., has been granted options to purchase 500,000 shares of common stock at an exercise price of $0.611 per share.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies Corp (NMTC), reported the sale of 8,981 shares of common stock through pre-scheduled transactions.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, sold a portion of his common stock holdings in two transactions on May 19 and May 20, 2025.

Mark Christianson, Business Development Director at NeuroOne Medical Technologies, reports acquisition of options to purchase 200,000 shares of common stock.